Novo Nordisk’s Zenagamtide Isn’t Chasing Ozempic — It’s Trying to Make Tirzepatide Obsolete
Novo Nordisk's zenagamtide hit 14.6% weight loss and 89.1% A1C control in Phase 2. Here's what the ADA 2026...
Type 2 Diabetes
Novo Nordisk’s Weekly Insulin Isn’t Just a Dosing Upgrade — It’s a Strategic Lifeline in a GLP-1 World
FDA approval of once-weekly insulin icodec-abae (Awiqli) gives Novo Nordisk a differentiated basal insulin, but peak sales of $1.2B...